| Year |
Citation |
Score |
| 2020 |
Srinivas N, Barbour AM, Epstein N, Zhou G, Petusky S, Xun Z, Yuska B, Marbury T, Chen X, Yeleswaram S, Punwani N. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib. Journal of Clinical Pharmacology. PMID 32149388 DOI: 10.1002/Jcph.1601 |
0.358 |
|
| 2019 |
Gong X, Darpo B, Xue H, Punwani N, He K, Barbour AM, Epstein N, Landman R, Chen X, Yeleswaram S. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants. Clinical Pharmacology in Drug Development. PMID 31821750 DOI: 10.1002/Cpdd.758 |
0.446 |
|
| 2019 |
Barbour AM, Punwani N, Epstein N, Landman R, Cimino E, Yuska B, Wang P, He K, Chen X, Yeleswaram S. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects. Journal of Clinical Pharmacology. PMID 31282592 DOI: 10.1002/Jcph.1484 |
0.399 |
|
| 2019 |
Barbour A, Zhang Y, Punwani N, Diamond S, Chen X, Yeleswaram S. 230 Dosing Strategy for Itacitinib, a Selective JAK1 Inhibitor, for the Treatment of Ulcerative Colitis The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000590452.10972.72 |
0.322 |
|
| 2019 |
Barbour AM, Chen X, Yeleswaram S. Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.256 |
0.379 |
|
| 2018 |
Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton JR, et al. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. Clinical and Translational Science. PMID 30040871 DOI: 10.1111/Cts.12565 |
0.335 |
|
| 2018 |
Upreti VV, Barbour AM. Antibiotics Development and the Emergence of Resistance: Clinical Pharmacology to the Rescue. Journal of Clinical Pharmacology. PMID 29329481 DOI: 10.1002/Jcph.1057 |
0.34 |
|
| 2017 |
Barbour AM, Fossler MJ. Infusions Are the Optimal Dosing Method in Intravenous ADME Studies Rather Than Bolus Dosing. Journal of Clinical Pharmacology. PMID 28815729 DOI: 10.1002/Jcph.991 |
0.361 |
|
| 2017 |
Byrne M, Donnellan W, Patel MR, Zeidan AM, Cherry M, Baer MR, Fathi AT, Kaplan J, Zhou F, Zheng F, Barbour AM, Savona MR. Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies Blood. 130: 2585-2585. DOI: 10.1182/Blood.V130.Suppl_1.2585.2585 |
0.404 |
|
| 2016 |
Deitchman A, de Jong D, Barbour A, Derendorf H. Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections. Expert Review of Anti-Infective Therapy. PMID 27690689 DOI: 10.1080/14787210.2016.1244481 |
0.526 |
|
| 2015 |
Barbour AM, Magee M, Shaddinger B, Arya N, Tombs L, Tao W, Patel BR, Fossler MJ, Glaser R. Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod. Journal of Clinical Pharmacology. 55: 661-70. PMID 25612153 DOI: 10.1002/Jcph.465 |
0.403 |
|
| 2014 |
Barbour AM, Gibiansky L, Wire MB. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of Clinical Pharmacology. 54: 206-14. PMID 25272370 DOI: 10.1002/Jcph.205 |
0.391 |
|
| 2014 |
Barbour AM, Fossler MJ, Barrett J. Practical considerations for dose selection in pediatric patients to ensure target exposure requirements. The Aaps Journal. 16: 749-55. PMID 24841797 DOI: 10.1208/S12248-014-9603-X |
0.366 |
|
| 2014 |
Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches. International Journal of Antimicrobial Agents. 43: 60-7. PMID 24183800 DOI: 10.1016/J.Ijantimicag.2013.08.016 |
0.599 |
|
| 2013 |
Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers. British Journal of Clinical Pharmacology. 76: 99-106. PMID 23215699 DOI: 10.1111/Bcp.12063 |
0.442 |
|
| 2011 |
Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatric Blood & Cancer. 57: 1049-54. PMID 21319285 DOI: 10.1002/Pbc.23011 |
0.377 |
|
| 2010 |
Barbour A, Derendorf H. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Therapeutics and Clinical Risk Management. 6: 485-95. PMID 20957140 DOI: 10.2147/Tcrm.S5823 |
0.57 |
|
| 2010 |
Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. International Journal of Antimicrobial Agents. 35: 431-8. PMID 20219329 DOI: 10.1016/J.Ijantimicag.2010.01.023 |
0.596 |
|
| 2009 |
Schmidt S, Sabarinath SN, Barbour A, Abbanat D, Manitpisitkul P, Sha S, Derendorf H. Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 53: 5039-45. PMID 19786607 DOI: 10.1128/Aac.00633-09 |
0.587 |
|
| 2009 |
Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, Derendorf H. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clinical Pharmacokinetics. 48: 575-84. PMID 19725592 DOI: 10.2165/11317100-000000000-00000 |
0.587 |
|
| 2009 |
Barbour A, Schmidt S, Rout WR, Ben-David K, Burkhardt O, Derendorf H. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. International Journal of Antimicrobial Agents. 34: 231-5. PMID 19411164 DOI: 10.1016/J.Ijantimicag.2009.03.019 |
0.54 |
|
| 2009 |
Barbour A, Schmidt S, Sabarinath SN, Grant M, Seubert C, Skee D, Murthy B, Derendorf H. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrobial Agents and Chemotherapy. 53: 2773-6. PMID 19364847 DOI: 10.1128/Aac.01409-08 |
0.598 |
|
| 2009 |
Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents. 34: 1-7. PMID 19261449 DOI: 10.1016/J.Ijantimicag.2008.12.012 |
0.585 |
|
| 2008 |
Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Current Opinion in Pharmacology. 8: 549-56. PMID 18625339 DOI: 10.1016/J.Coph.2008.06.010 |
0.499 |
|
| Show low-probability matches. |